Logo image of MNMD

MIND MEDICINE MINDMED INC (MNMD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MNMD - CA60255C8850 - Common Stock

12.09 USD
+0.21 (+1.77%)
Last: 11/26/2025, 2:19:27 PM
Fundamental Rating

1

Taking everything into account, MNMD scores 1 out of 10 in our fundamental rating. MNMD was compared to 192 industry peers in the Pharmaceuticals industry. MNMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MNMD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MNMD has reported negative net income.
MNMD had a negative operating cash flow in the past year.
MNMD had negative earnings in each of the past 5 years.
In the past 5 years MNMD always reported negative operating cash flow.
MNMD Yearly Net Income VS EBIT VS OCF VS FCFMNMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

MNMD's Return On Assets of -70.95% is on the low side compared to the rest of the industry. MNMD is outperformed by 70.31% of its industry peers.
MNMD's Return On Equity of -128.72% is on the low side compared to the rest of the industry. MNMD is outperformed by 66.15% of its industry peers.
Industry RankSector Rank
ROA -70.95%
ROE -128.72%
ROIC N/A
ROA(3y)-48.75%
ROA(5y)-48.92%
ROE(3y)-68.39%
ROE(5y)-62.24%
ROIC(3y)N/A
ROIC(5y)N/A
MNMD Yearly ROA, ROE, ROICMNMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MNMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MNMD Yearly Profit, Operating, Gross MarginsMNMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

MNMD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MNMD has more shares outstanding
MNMD has a better debt/assets ratio than last year.
MNMD Yearly Shares OutstandingMNMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MNMD Yearly Total Debt VS Total AssetsMNMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

MNMD has an Altman-Z score of 2.12. This is not the best score and indicates that MNMD is in the grey zone with still only limited risk for bankruptcy at the moment.
MNMD's Altman-Z score of 2.12 is fine compared to the rest of the industry. MNMD outperforms 60.94% of its industry peers.
MNMD has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
MNMD has a Debt to Equity ratio (0.31) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 2.12
ROIC/WACCN/A
WACCN/A
MNMD Yearly LT Debt VS Equity VS FCFMNMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

MNMD has a Current Ratio of 3.30. This indicates that MNMD is financially healthy and has no problem in meeting its short term obligations.
MNMD has a Current ratio (3.30) which is comparable to the rest of the industry.
A Quick Ratio of 3.30 indicates that MNMD has no problem at all paying its short term obligations.
The Quick ratio of MNMD (3.30) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.3
Quick Ratio 3.3
MNMD Yearly Current Assets VS Current LiabilitesMNMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

MNMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.27%, which is quite good.
EPS 1Y (TTM)13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-188.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MNMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.57% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y12.91%
EPS Next 2Y4.86%
EPS Next 3Y5.5%
EPS Next 5Y11.57%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MNMD Yearly Revenue VS EstimatesMNMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
MNMD Yearly EPS VS EstimatesMNMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MNMD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MNMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNMD Price Earnings VS Forward Price EarningsMNMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNMD Per share dataMNMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.86%
EPS Next 3Y5.5%

More info and screens

0

5. Dividend

5.1 Amount

MNMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIND MEDICINE MINDMED INC

NASDAQ:MNMD (11/26/2025, 2:19:27 PM)

12.09

+0.21 (+1.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-04 2026-03-04/amc
Inst Owners55.73%
Inst Owner Change-4.05%
Ins Owners1.05%
Ins Owner Change-2.56%
Market Cap1.19B
Revenue(TTM)N/A
Net Income(TTM)-168.10M
Analysts84.44
Price Target26.15 (116.29%)
Short Float %15.72%
Short Ratio6.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-43.53%
Min EPS beat(2)-52.55%
Max EPS beat(2)-34.51%
EPS beat(4)1
Avg EPS beat(4)-23.85%
Min EPS beat(4)-52.55%
Max EPS beat(4)27.56%
EPS beat(8)3
Avg EPS beat(8)-25.48%
EPS beat(12)5
Avg EPS beat(12)-13.29%
EPS beat(16)9
Avg EPS beat(16)-0.85%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.55%
PT rev (3m)2.55%
EPS NQ rev (1m)0.14%
EPS NQ rev (3m)-1.54%
EPS NY rev (1m)0.31%
EPS NY rev (3m)-23.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.12
P/tB 10.76
EV/EBITDA N/A
EPS(TTM)-1.96
EYN/A
EPS(NY)-1.87
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0
BVpS1.33
TBVpS1.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -70.95%
ROE -128.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.75%
ROA(5y)-48.92%
ROE(3y)-68.39%
ROE(5y)-62.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.3
Quick Ratio 3.3
Altman-Z 2.12
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-188.89%
EPS Next Y12.91%
EPS Next 2Y4.86%
EPS Next 3Y5.5%
EPS Next 5Y11.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-61.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-53.26%
EBIT Next 3Y-12.96%
EBIT Next 5Y19.82%
FCF growth 1Y-101.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.12%
OCF growth 3YN/A
OCF growth 5YN/A

MIND MEDICINE MINDMED INC / MNMD FAQ

Can you provide the ChartMill fundamental rating for MIND MEDICINE MINDMED INC?

ChartMill assigns a fundamental rating of 1 / 10 to MNMD.


Can you provide the valuation status for MIND MEDICINE MINDMED INC?

ChartMill assigns a valuation rating of 0 / 10 to MIND MEDICINE MINDMED INC (MNMD). This can be considered as Overvalued.


How profitable is MIND MEDICINE MINDMED INC (MNMD) stock?

MIND MEDICINE MINDMED INC (MNMD) has a profitability rating of 0 / 10.


What is the expected EPS growth for MIND MEDICINE MINDMED INC (MNMD) stock?

The Earnings per Share (EPS) of MIND MEDICINE MINDMED INC (MNMD) is expected to grow by 12.91% in the next year.